Data J L, Rane A, Gerkens J, Wilkinson G R, Nies A S, Branch R A
J Pharmacol Exp Ther. 1978 Aug;206(2):431-8.
Indomethacin has the potential to interact with furosemide in a number of different fashions. We have investigated some of these possibilities in seven mongrel dogs that received furosemide (2 mg/kg i.v.). Plasma and urinary concentration of furosemide were measured by high performance liquid chromatography, diuretic response was assessed by urinary sodium excretion and renal blood flow and its distribution were estimated using the radioactive microsphere technique. Furosemide induced a prompt diuresis associated with a 50% increase in total renal blood flow. Intrarenal blood flow was preferentially increased in the inner cortical zones. Furosemide was rapidly eliminated with a renal clearance that was 35% of the total systemic clearance. Maximal sodium excretion was attained at plasma furosemide concentrations greater than 0.8 microgram/ml; below this concentration there was a linear relationship between plasma concentration and rate of sodium excretion. The ratio of sodium/furosemide concentration in urine rose to a plateau, then remained constant. Indomethacin pretreatment inhibited the hemodynamic response to furosemide. In addition, indomethacin reduced the renal and extrarenal clearance of furosemide by approximately 30%, but did not change the proportion of unchanged drug excreted in the urine. Although the diuretic response for any given plasma concentration of furosemide was reduced, the ratio of urinary sodium/furosemide concentration was not changed by indomethacin. Since the amount of furosemide reaching the urine was not altered, the total diuretic response was not significantly affected by indomethacin. From these observations we conclude that indomethacin alters the pharmacokinetics of the disposition of furosemide and furosemide-induced renal hemodynamic changes. However, our data indicate that the response of the renal tubule to furosemide secreted into tubular fluid is not changed by indomethacin.
吲哚美辛有可能以多种不同方式与呋塞米相互作用。我们在7只接受呋塞米(2毫克/千克静脉注射)的杂种狗身上研究了其中一些可能性。通过高效液相色谱法测量呋塞米的血浆和尿液浓度,通过尿钠排泄评估利尿反应,并使用放射性微球技术估计肾血流量及其分布。呋塞米引起迅速利尿,同时肾总血流量增加50%。肾内血流量在内皮质区优先增加。呋塞米迅速消除,其肾清除率占全身总清除率的35%。当血浆呋塞米浓度大于0.8微克/毫升时达到最大钠排泄;低于此浓度时,血浆浓度与钠排泄率之间呈线性关系。尿中钠/呋塞米浓度比上升至平台期,然后保持恒定。吲哚美辛预处理抑制了对呋塞米的血流动力学反应。此外,吲哚美辛使呋塞米的肾清除率和肾外清除率降低约30%,但未改变尿中排泄的原形药物比例。尽管对于任何给定血浆浓度的呋塞米,利尿反应降低,但吲哚美辛并未改变尿钠/呋塞米浓度比。由于到达尿液的呋塞米量未改变,吲哚美辛对总利尿反应没有显著影响。从这些观察结果我们得出结论,吲哚美辛改变了呋塞米处置的药代动力学以及呋塞米诱导的肾血流动力学变化。然而,我们的数据表明,吲哚美辛并未改变肾小管对分泌到肾小管液中的呋塞米的反应。